411 related articles for article (PubMed ID: 36719097)
21. [Finerenone (Kerendia®), a new weapon against the chronic kidney disease of a patient with type 2 diabetes].
Scheen A; Delanaye P
Rev Med Liege; 2023 Dec; 78(12):725-732. PubMed ID: 38095038
[TBL] [Abstract][Full Text] [Related]
22. Finerenone: towards a holistic therapeutic approach to patients with diabetic kidney disease.
Górriz JL; González-Juanatey JR; Facila L; Soler MJ; Valle A; Ortiz A
Nefrologia (Engl Ed); 2023; 43(4):386-398. PubMed ID: 37813743
[TBL] [Abstract][Full Text] [Related]
23. Finerenone: a mineralocorticoid receptor antagonist for the treatment of chronic kidney disease associated with type 2 diabetes.
Lerma EV; Wilson DJ
Expert Rev Clin Pharmacol; 2022 May; 15(5):501-513. PubMed ID: 35762406
[TBL] [Abstract][Full Text] [Related]
24. Nonsteroidal Mineralocorticoid Receptor Antagonism by Finerenone-Translational Aspects and Clinical Perspectives across Multiple Organ Systems.
Kolkhof P; Lawatscheck R; Filippatos G; Bakris GL
Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012508
[TBL] [Abstract][Full Text] [Related]
25. Optimization of potassium management in patients with chronic kidney disease and type 2 diabetes on finerenone.
Ortiz A; Alcázar Arroyo R; Casado Escribano PP; Fernández-Fernández B; Martínez Debén F; Mediavilla JD; Michan-Doña A; Soler MJ; Gorriz JL
Expert Rev Clin Pharmacol; 2023; 16(6):519-531. PubMed ID: 37190957
[TBL] [Abstract][Full Text] [Related]
26. Mineralocorticoid receptor antagonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease.
Ortiz A; Ferro CJ; Balafa O; Burnier M; Ekart R; Halimi JM; Kreutz R; Mark PB; Persu A; Rossignol P; Ruilope LM; Schmieder RE; Valdivielso JM; Del Vecchio L; Zoccali C; Mallamaci F; Sarafidis P;
Nephrol Dial Transplant; 2023 Jan; 38(1):10-25. PubMed ID: 33944938
[TBL] [Abstract][Full Text] [Related]
27. Non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease.
Pandey AK; Bhatt DL; Cosentino F; Marx N; Rotstein O; Pitt B; Pandey A; Butler J; Verma S
Eur Heart J; 2022 Aug; 43(31):2931-2945. PubMed ID: 35713973
[TBL] [Abstract][Full Text] [Related]
28. Therapeutic perspective: evolving evidence of nonsteroidal mineralocorticoid receptor antagonists in diabetic kidney disease.
Yao L; Liang X; Wang P
Am J Physiol Endocrinol Metab; 2023 Jun; 324(6):E531-E541. PubMed ID: 37166263
[TBL] [Abstract][Full Text] [Related]
29. Mineralcorticoid receptor blockers in chronic kidney disease.
Erraez S; López-Mesa M; Gómez-Fernández P
Nefrologia (Engl Ed); 2021; 41(3):258-275. PubMed ID: 36166243
[TBL] [Abstract][Full Text] [Related]
30. Kidney outcomes with finerenone: an analysis from the FIGARO-DKD study.
Ruilope LM; Pitt B; Anker SD; Rossing P; Kovesdy CP; Pecoits-Filho R; Pergola P; Joseph A; Lage A; Mentenich N; Scheerer MF; Bakris GL
Nephrol Dial Transplant; 2023 Feb; 38(2):372-383. PubMed ID: 35451488
[TBL] [Abstract][Full Text] [Related]
31. The Role of the Non-Steroidal Mineralocorticoid Antagonist Finerenone in Cardiorenal Management.
Beavers CJ
Curr Cardiol Rep; 2022 Dec; 24(12):1785-1790. PubMed ID: 36272052
[TBL] [Abstract][Full Text] [Related]
32. The non-steroidal mineralocorticoid receptor antagonist finerenone is a novel therapeutic option for patients with Type 2 diabetes and chronic kidney disease.
Barrera-Chimal J; Gerarduzzi C; Rossignol P; Jaisser F
Clin Sci (Lond); 2022 Jun; 136(12):1005-1017. PubMed ID: 35765983
[TBL] [Abstract][Full Text] [Related]
33. Aldosterone, Mineralocorticoid Receptor Activation, and CKD: A Review of Evolving Treatment Paradigms.
Epstein M; Kovesdy CP; Clase CM; Sood MM; Pecoits-Filho R
Am J Kidney Dis; 2022 Nov; 80(5):658-666. PubMed ID: 36057467
[TBL] [Abstract][Full Text] [Related]
34. Finerenone Reduces New-Onset Atrial Fibrillation in Patients With Chronic Kidney Disease and Type 2 Diabetes.
Filippatos G; Bakris GL; Pitt B; Agarwal R; Rossing P; Ruilope LM; Butler J; Lam CSP; Kolkhof P; Roberts L; Tasto C; Joseph A; Anker SD;
J Am Coll Cardiol; 2021 Jul; 78(2):142-152. PubMed ID: 34015478
[TBL] [Abstract][Full Text] [Related]
35. Modifiability of Composite Cardiovascular Risk Associated With Chronic Kidney Disease in Type 2 Diabetes With Finerenone.
Agarwal R; Pitt B; Rossing P; Anker SD; Filippatos G; Ruilope LM; Kovesdy CP; Tuttle K; Vaduganathan M; Wanner C; Bansilal S; Gebel M; Joseph A; Lawatscheck R; Bakris GL
JAMA Cardiol; 2023 Aug; 8(8):732-741. PubMed ID: 37314801
[TBL] [Abstract][Full Text] [Related]
36. Finerenone and effects on mortality in chronic kidney disease and type 2 diabetes: a FIDELITY analysis.
Filippatos G; Anker SD; August P; Coats AJS; Januzzi JL; Mankovsky B; Rossing P; Ruilope LM; Pitt B; Sarafidis P; Teerlink JR; Kapelios CJ; Gebel M; Brinker M; Joseph A; Lage A; Bakris G; Agarwal R
Eur Heart J Cardiovasc Pharmacother; 2023 Feb; 9(2):183-191. PubMed ID: 36639130
[TBL] [Abstract][Full Text] [Related]
37. Rationale and design of an investigator-initiated, multicenter, prospective, placebo-controlled, double-blind, randomized trial to evaluate the effects of finerenone on vascular stiffness and cardiorenal biomarkers in type 2 diabetes and chronic kidney disease (FIVE-STAR).
Tanaka A; Shibata H; Imai T; Yoshida H; Miyazono M; Takahashi N; Fukuda D; Okada Y; Teragawa H; Suwa S; Kida K; Moroi M; Taguchi I; Toyoda S; Shimabukuro M; Tanabe K; Tanaka K; Nangaku M; Node K;
Cardiovasc Diabetol; 2023 Jul; 22(1):194. PubMed ID: 37525257
[TBL] [Abstract][Full Text] [Related]
38. Estimated Lifetime Cardiovascular, Kidney, and Mortality Benefits of Combination Treatment With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Nonsteroidal MRA Compared With Conventional Care in Patients With Type 2 Diabetes and Albuminuria.
Neuen BL; Heerspink HJL; Vart P; Claggett BL; Fletcher RA; Arnott C; de Oliveira Costa J; Falster MO; Pearson SA; Mahaffey KW; Neal B; Agarwal R; Bakris G; Perkovic V; Solomon SD; Vaduganathan M
Circulation; 2024 Feb; 149(6):450-462. PubMed ID: 37952217
[TBL] [Abstract][Full Text] [Related]
39. Novel Therapies in Diabetic Kidney Disease and Risk of Hyperkalemia: A Review of the Evidence From Clinical Trials.
Albakr RB; Sridhar VS; Cherney DZI
Am J Kidney Dis; 2023 Dec; 82(6):737-742. PubMed ID: 37517546
[TBL] [Abstract][Full Text] [Related]
40. Cardiovascular-renal protective effect and molecular mechanism of finerenone in type 2 diabetic mellitus.
Lv R; Xu L; Che L; Liu S; Wang Y; Dong B
Front Endocrinol (Lausanne); 2023; 14():1125693. PubMed ID: 36860374
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
